Nonetheless, some researchers advocated the expression of CD44 as a biomarker associated with some clinicopathological features of the tumor, such as high-grade, more advanced FIGO stage, or the presence of residual disease and drug resistance [43,44]. Here, CD44 is linked to neoplasm.